Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline

https://ift.tt/ANKp8mk Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Imm...

Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)

https://ift.tt/Aqzhbya from Sanofi - Aventis Groupe https://ift.tt/PQMzayZ via IFTTT " May good health envelop you, spurring a quic...

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

https://ift.tt/Kl9DIjw   from Sanofi - Aventis Groupe https://ift.tt/ZbBke74 via IFTTT " May good health envelop you, spurring a q...

Media Update: Dupixent® (dupilumab) U.S. label updated with data further supporting use in atopic dermatitis with moderate-to-severe hand and foot involvement

https://ift.tt/s0lOVQM from Sanofi - Aventis Groupe https://ift.tt/CLPUQ4n via IFTTT " May good health envelop you, spurring a quic...

Press Release: Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee

https://ift.tt/jkugvqX   from Sanofi - Aventis Groupe https://ift.tt/W3z9Rxg via IFTTT " May good health envelop you, spurring a q...

Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint

https://ift.tt/os9kIx3 Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a prima...

Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa

https://ift.tt/mFePvaq   from Sanofi - Aventis Groupe https://ift.tt/3Npy0tz via IFTTT " May good health envelop you, spurring a q...